Effects of oxytocin administration on salivary sex hormone levels in autistic and neurotypical women.
Autism
Autistic women
Oestradiol
Oxytocin
Salivary hormone levels
Sex steroids
Testosterone
Journal
Molecular autism
ISSN: 2040-2392
Titre abrégé: Mol Autism
Pays: England
ID NLM: 101534222
Informations de publication
Date de publication:
18 03 2020
18 03 2020
Historique:
received:
19
09
2019
accepted:
09
03
2020
entrez:
20
3
2020
pubmed:
20
3
2020
medline:
1
1
2021
Statut:
epublish
Résumé
Oxytocin administration, which may be of therapeutic value for individuals with social difficulties, is likely to affect endogenous levels of other socially relevant hormones. However, to date, the effects of oxytocin administration on endogenous hormones have only been examined in neurotypical individuals. The need to consider multi-hormone interactions is particularly warranted in oxytocin trials for autism due to evidence of irregularities in both oxytocin and sex steroid systems. In this double-blind cross-over study, saliva samples were collected from 16 autistic and 29 neurotypical women before and after intranasal administration of 24 IU oxytocin or placebo. Oestradiol, testosterone, and oxytocin levels were quantified in saliva samples. Participants also completed the Autism-Spectrum Quotient (AQ) and Empathy Quotient (EQ) questionnaires. Distinct patterns of change in testosterone and oestradiol levels pre- to-post-administration were observed in autistic relative to neurotypical women (ANCOVA, p < 0.05 main effect of Group), controlling for sample collection time. The mean percent change oestradiol was + 8.8% for the autism group and - 13.0% for the neurotypical group (t = 1.81, p = 0.08), while the mean percent change testosterone was + 1.1% in the autism group and - 12.6% in the neurotypical group (t = 1.26, p = 0.22). In the oxytocin condition, the mean percent change oestradiol was + 12.6% in the autism group and - 6.9% in the neurotypical group (t = 1.78, p = 0.08), while the mean percent change testosterone was + 14.4% in the autism group and - 15.2% in the neurotypical group (t = 3.00, p = 0.006). Robust regression confirmed that group differences in percent change hormone levels were not driven by a small number of influential individuals. Baseline hormone levels did not differ between groups when considered individually. However, baseline testosterone relative to oestradiol (T:E2 ratio) was higher in autistic women (p = 0.023, Cohen's d = 0.63), and this ratio correlated positively and negatively with AQ and EQ scores, respectively, in the combined sample. Further studies with larger and more diverse autistic sample are warranted to confirm these effects. This study provides the first evidence that oxytocin influences endogenous testosterone levels in autistic individuals, with autistic women showing increases similar to previous reports of neurotypical men. These findings highlight the need to consider sex steroid hormones as a variable in future oxytocin trials.
Sections du résumé
BACKGROUND
Oxytocin administration, which may be of therapeutic value for individuals with social difficulties, is likely to affect endogenous levels of other socially relevant hormones. However, to date, the effects of oxytocin administration on endogenous hormones have only been examined in neurotypical individuals. The need to consider multi-hormone interactions is particularly warranted in oxytocin trials for autism due to evidence of irregularities in both oxytocin and sex steroid systems.
METHODS
In this double-blind cross-over study, saliva samples were collected from 16 autistic and 29 neurotypical women before and after intranasal administration of 24 IU oxytocin or placebo. Oestradiol, testosterone, and oxytocin levels were quantified in saliva samples. Participants also completed the Autism-Spectrum Quotient (AQ) and Empathy Quotient (EQ) questionnaires.
RESULTS
Distinct patterns of change in testosterone and oestradiol levels pre- to-post-administration were observed in autistic relative to neurotypical women (ANCOVA, p < 0.05 main effect of Group), controlling for sample collection time. The mean percent change oestradiol was + 8.8% for the autism group and - 13.0% for the neurotypical group (t = 1.81, p = 0.08), while the mean percent change testosterone was + 1.1% in the autism group and - 12.6% in the neurotypical group (t = 1.26, p = 0.22). In the oxytocin condition, the mean percent change oestradiol was + 12.6% in the autism group and - 6.9% in the neurotypical group (t = 1.78, p = 0.08), while the mean percent change testosterone was + 14.4% in the autism group and - 15.2% in the neurotypical group (t = 3.00, p = 0.006). Robust regression confirmed that group differences in percent change hormone levels were not driven by a small number of influential individuals. Baseline hormone levels did not differ between groups when considered individually. However, baseline testosterone relative to oestradiol (T:E2 ratio) was higher in autistic women (p = 0.023, Cohen's d = 0.63), and this ratio correlated positively and negatively with AQ and EQ scores, respectively, in the combined sample.
LIMITATIONS
Further studies with larger and more diverse autistic sample are warranted to confirm these effects.
CONCLUSIONS
This study provides the first evidence that oxytocin influences endogenous testosterone levels in autistic individuals, with autistic women showing increases similar to previous reports of neurotypical men. These findings highlight the need to consider sex steroid hormones as a variable in future oxytocin trials.
Identifiants
pubmed: 32188502
doi: 10.1186/s13229-020-00326-5
pii: 10.1186/s13229-020-00326-5
pmc: PMC7079504
doi:
Substances chimiques
Testosterone
3XMK78S47O
Estradiol
4TI98Z838E
Oxytocin
50-56-6
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20Références
Physiol Behav. 2010 Jan 12;99(1):8-16
pubmed: 19833145
Brain Res. 2014 Sep 11;1580:22-56
pubmed: 24468203
Physiol Behav. 1996 Nov;60(5):1209-15
pubmed: 8916173
Physiol Behav. 1990 Jul;48(1):83-6
pubmed: 2236282
Front Neuroendocrinol. 2017 Oct;47:1-18
pubmed: 28676436
Physiol Behav. 2013 Jun 13;118:159-64
pubmed: 23685236
Curr Opin Behav Sci. 2018 Oct;23:136-142
pubmed: 31745496
Psychoneuroendocrinology. 2013 May;38(5):626-7
pubmed: 23582729
Biol Reprod. 1995 Jun;52(6):1268-73
pubmed: 7632835
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Mar 3;49:47-52
pubmed: 24252717
Clin Chem. 2008 Nov;54(11):1759-69
pubmed: 18757583
Mol Psychiatry. 2011 Dec;16(12):1213-20
pubmed: 20877284
Biol Psychiatry. 2016 Feb 1;79(3):234-42
pubmed: 26257243
Psychoneuroendocrinology. 2016 Jan;63:385-97
pubmed: 26521052
Mol Psychiatry. 2013 Sep;18(9):958-60
pubmed: 23147382
J Child Psychol Psychiatry. 2017 Apr;58(4):411-435
pubmed: 28102566
Mol Psychiatry. 2015 Mar;20(3):369-76
pubmed: 24888361
Proc Natl Acad Sci U S A. 2018 Nov 27;115(48):12152-12157
pubmed: 30420503
Front Behav Neurosci. 2014 Feb 17;8:48
pubmed: 24596548
PLoS One. 2016 Nov 18;11(11):e0166617
pubmed: 27861588
Horm Behav. 2020 Jan;117:104607
pubmed: 31654674
Pharmacopsychiatry. 2017 Jan;50(1):5-13
pubmed: 27574858
PLoS One. 2013 Sep 25;8(9):e74849
pubmed: 24086383
Neurosci Biobehav Rev. 2017 May;76(Pt A):87-98
pubmed: 28434591
Proc Natl Acad Sci U S A. 2017 Jul 25;114(30):8119-8124
pubmed: 28696286
Transl Psychiatry. 2013 May 21;3:e258
pubmed: 23695233
Neuropsychopharmacology. 2017 Sep;42(10):2064-2071
pubmed: 28447621
J Neuroendocrinol. 2018 Apr 3;:e12596
pubmed: 29611254
Ther Deliv. 2018 Jul;9(7):515-525
pubmed: 29943688
Transl Psychiatry. 2017 Apr 18;7(4):e1099
pubmed: 28418398
Horm Behav. 2006 Jun;50(1):148-53
pubmed: 16624315
Peptides. 2013 Feb;40:99-103
pubmed: 23246527
J Neuroendocrinol. 2004 Apr;16(4):319-24
pubmed: 15089969
Soc Neurosci. 2006;1(2):135-48
pubmed: 18633782
PLoS One. 2018 Jun 14;13(6):e0198779
pubmed: 29902186
Mol Autism. 2014 Apr 09;5:27
pubmed: 24717046
Biol Rev Camb Philos Soc. 2016 May;91(2):390-408
pubmed: 25631363
Br J Psychiatry. 2014 Aug;205(2):107-12
pubmed: 24855128
PLoS Biol. 2011 Jun;9(6):e1001081
pubmed: 21695109
Psychoneuroendocrinology. 2011 Sep;36(8):1154-63
pubmed: 21398041
Psychol Rev. 2000 Jul;107(3):411-29
pubmed: 10941275
Transl Psychiatry. 2018 Aug 1;8(1):136
pubmed: 30065244
J Neuroendocrinol. 1993 Dec;5(6):619-28
pubmed: 8680433
Psychoneuroendocrinology. 2018 Jan;87:9-19
pubmed: 29032324
J Neurosci. 1991 Jul;11(7):2032-8
pubmed: 1648603
Neuropeptides. 2012 Oct;46(5):211-5
pubmed: 22884888
J Autism Dev Disord. 2001 Feb;31(1):5-17
pubmed: 11439754
Sci Rep. 2018 May 16;8(1):7672
pubmed: 29769663
Front Neuroendocrinol. 2016 Jan;40:1-23
pubmed: 25951955
Mol Psychiatry. 2019 Jul 29;:
pubmed: 31358906
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12258-63
pubmed: 25092315
Eur Neuropsychopharmacol. 2020 Jan;30:87-101
pubmed: 30201120
Nat Rev Neurosci. 2011 Aug 19;12(9):524-38
pubmed: 21852800
Cell Tissue Res. 1989;256(2):411-7
pubmed: 2731224